Medulloblastoma, the most common malignant brain tumor in childhood, continues to represent a therapeutic challenge. Despite treatment with increasingly sophisticated surgical and radiotherapeutic intervention, the majority of children with this tumor will ultimately die of progressive disease. Although the role of chemotherapy in the treatment of medulloblastoma remains poorly defined, recently clinical and laboratory studies support the activity of the classical bifunctional alkylating agents against these tumors. Studies in our laboratory have documented the activity of a series of bifunctional alkylating agents including cyclophosphamide and melphalan in the treatment of a panel of medulloblastoma cell lines and transplantable xenografts. Clinical trials have confirmed the activity of cyclophosphamide and melphalan in the treatment of patients with recurrent medulloblastoma. Unfortunately, meaningful increases in the survival of patients with medulloblastoma have not yet resulted from the use of alkylating agents, a limitation due in large part to intrinsic or acquired alkylator resistance in a subset of cells in these tumors. The hypothesis of this proposal is that modulation of glutathione metabolism can enhance bifunctional alkylating agent therapy of sensitive and resistant tumor cells.
The specific aims of this proposal are: 1) To define the role and mechanism(s) of glutathione in modulating the activity of melphalan and cyclophosphamide (4- hydroperoxycyclophosphamide) in alkylator-sensitive and -resistant human medulloblastoma cell lines and xenografts in athymic nude mice, 2) to define the effects of gamma-glutamylcysteine synthetase and gamma-glutamyl transpeptidase inhibitors on the activity and toxicity of nitrogen mustard- based alkylating agents in the treatment of alkylator-sensitive and - resistant human medulloblastoma cell lines and xenografts in athymic nude mice, 3) to define the effects of BSO-mediated glutathione depletion on the activity and toxicity of intrathecal malphalan in the treatment of leptomeningeal human medulloblastoma in athymic nude rats.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
2R01NS030245-05A1
Application #
3417230
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1992-06-22
Project End
1995-05-31
Budget Start
1992-06-22
Budget End
1993-05-31
Support Year
5
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Duke University
Department
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Cui, B; Johnson, S P; Bullock, N et al. (2009) Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway. Mol Pharmacol 75:1356-63
Bacolod, Manny D; Fehdrau, Randy; Johnson, Stewart P et al. (2009) BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line. Cancer Chemother Pharmacol 63:753-8
Maxwell, Jill A; Johnson, Stewart P; McLendon, Roger E et al. (2008) Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res 14:4859-68
Bacolod, M D; Lin, S M; Johnson, S P et al. (2008) The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide. Curr Cancer Drug Targets 8:172-9
Maxwell, Jill A; Johnson, Stewart P; Quinn, Jennifer A et al. (2006) Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther 5:2531-9
Rich, Jeremy N; Sathornsumetee, Sith; Keir, Stephen T et al. (2005) ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 11:8145-57
Quinn, Jennifer A; Desjardins, Annick; Weingart, Jon et al. (2005) Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 23:7178-87
Cheng, C Lynn; Johnson, Stewart P; Keir, Stephen T et al. (2005) Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 4:1364-8
Goudar, Ranjit K; Shi, Qing; Hjelmeland, Mark D et al. (2005) Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4:101-12
Bacolod, Manny D; Johnson, Stewart P; Pegg, Anthony E et al. (2004) Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. Mol Cancer Ther 3:1127-35

Showing the most recent 10 out of 37 publications